Deutsche Bank AG Acquires 151,927 Shares of ResMed Inc. (NYSE:RMD)

Deutsche Bank AG boosted its position in ResMed Inc. (NYSE:RMD - Free Report) by 34.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 597,833 shares of the medical equipment provider's stock after buying an additional 151,927 shares during the quarter. Deutsche Bank AG owned 0.41% of ResMed worth $136,718,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of ResMed by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 18,173,462 shares of the medical equipment provider's stock valued at $4,156,089,000 after purchasing an additional 160,590 shares in the last quarter. Geode Capital Management LLC grew its position in shares of ResMed by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 3,944,084 shares of the medical equipment provider's stock valued at $899,860,000 after buying an additional 85,270 shares during the last quarter. Invesco Ltd. grew its position in shares of ResMed by 32.2% during the 4th quarter. Invesco Ltd. now owns 2,325,009 shares of the medical equipment provider's stock valued at $531,706,000 after buying an additional 566,046 shares during the last quarter. Northern Trust Corp grew its position in shares of ResMed by 20.6% during the 4th quarter. Northern Trust Corp now owns 1,702,590 shares of the medical equipment provider's stock valued at $389,365,000 after buying an additional 290,664 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of ResMed by 3.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 957,020 shares of the medical equipment provider's stock valued at $218,861,000 after buying an additional 32,973 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on RMD shares. UBS Group dropped their price target on shares of ResMed from $290.00 to $285.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. JPMorgan Chase & Co. raised their price target on shares of ResMed from $286.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, April 24th. The Goldman Sachs Group started coverage on shares of ResMed in a research note on Thursday, January 16th. They issued a "buy" rating on the stock. Citigroup upgraded shares of ResMed from a "neutral" rating to a "buy" rating in a research note on Wednesday, March 5th. Finally, KeyCorp set a $274.00 price target on shares of ResMed in a research note on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $258.83.

Insider Activity at ResMed

In related news, CEO Michael J. Farrell sold 8,009 shares of ResMed stock in a transaction on Friday, March 7th. The shares were sold at an average price of $229.20, for a total value of $1,835,662.80. Following the transaction, the chief executive officer now owns 455,472 shares in the company, valued at $104,394,182.40. This trade represents a 1.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kaushik Ghoshal sold 9,745 shares of ResMed stock in a transaction on Monday, March 10th. The stock was sold at an average price of $239.31, for a total transaction of $2,332,075.95. Following the completion of the transaction, the insider now owns 9,725 shares in the company, valued at $2,327,289.75. This trade represents a 50.05% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 48,949 shares of company stock valued at $11,335,320. Insiders own 0.71% of the company's stock.

ResMed Trading Down 0.4%

Shares of NYSE:RMD traded down $1.02 during mid-day trading on Wednesday, hitting $246.63. The stock had a trading volume of 1,074,863 shares, compared to its average volume of 1,013,044. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. The company has a market cap of $36.16 billion, a PE ratio of 29.12, a P/E/G ratio of 1.53 and a beta of 0.78. ResMed Inc. has a 12-month low of $179.42 and a 12-month high of $263.05. The company's 50 day moving average is $224.30 and its 200-day moving average is $234.08.

ResMed (NYSE:RMD - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.36 by $0.01. ResMed had a net margin of 25.34% and a return on equity of 26.17%. The company had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter in the prior year, the firm earned $2.13 EPS. The company's revenue was up 7.9% compared to the same quarter last year. On average, sell-side analysts predict that ResMed Inc. will post 9.47 EPS for the current year.

ResMed Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 12th. Investors of record on Thursday, May 8th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend is Thursday, May 8th. ResMed's payout ratio is presently 23.79%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.